Intarcia Announces Upcoming Presentation At 34th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 7, 2016 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview at 9:00 am Pacific Time on Monday, January 11th, at the J.P. Morgan 34th Annual Healthcare Conference. The presentation will be given in the Elizabethan Meeting Room (C & D) at the Westin St. Francis Hotel, San Francisco, CA.

Intarcia logo

About Intarcia Therapeutics

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing novel therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration for better adherence rates over time, and improved tolerability of drug therapies. Delivering medicines just once or twice yearly in Intarcia's proprietary technologies has the potential to improve efficacy as well as patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins, peptides and antibody fragments at above-body temperatures for long periods of time and to deliver them in a precise and consistent manner over the course of a full year. Intarcia has nearly completed conducting its Phase 3-stage development program for type 2 diabetes. It consisted of four separate clinical trials. The results of those trials are now being prepared for filings. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic serious disorders in the field of diabetes, obesity and autoimmune disorders. For more information on the Company, please visit

Logo -


To view the original version on PR Newswire, visit:

SOURCE Intarcia Therapeutics, Inc.

Back to news